Safety issues from a Phase 3 clinical trial of a live-attenuated chimeric yellow fever tetravalent dengue vaccine
A tetravalent live-attenuated 3-dose vaccine composed of chimeras of yellow fever 17D and the four dengue viruses (CYD, also called Dengvaxia) completed phase 3 clinical testing in over 35,000 children leading to a recommendation that vaccine be administered to >/ = 9 year-olds residing in highly...
में बचाया:
| मुख्य लेखक: | |
|---|---|
| स्वरूप: | पुस्तक |
| प्रकाशित: |
Taylor & Francis Group,
2018-09-01T00:00:00Z.
|
| विषय: | |
| ऑनलाइन पहुंच: | Connect to this object online. |
| टैग: |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|
इंटरनेट
Connect to this object online.3rd Floor Main Library
| बोधानक: |
A1234.567 |
|---|---|
| प्रति 1 | उपलब्ध |